中国麻风皮肤病杂志 ›› 2022, Vol. 38 ›› Issue (2): 135-138.doi: 10.12144/zgmfskin202202135

• 综述 • 上一篇    

免疫检测点抑制剂皮肤相关不良反应

刘韵祎,姜沛彧,李敏,陶梦,刘乙萱,张嘉文,南宇晴,许阳   

  1. 南京医科大学第一附属医院皮肤科，南京，210029
  • 出版日期:2022-02-15 发布日期:2021-12-22
  • 通讯作者: 许阳, E-mail: cardioos@163.com

Cutaneous adverse effects of immune-checkpoint inhibitors

LIU Yunyi, JIANG Peiyu, LI Min, TAO Meng, LIU Yixuan, ZHANG Jiawen, NAN Yuqing, XU Yang   

  1. Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
  • Online:2022-02-15 Published:2021-12-22
  • Contact: XU Yang, E-mail: cardioos@163.com

PDF (PC)

250

摘要： 免疫检测点抑制剂（immune-checkpoint inhibitors, ICIs）是近10年癌症治疗领域最重要的进展，包括抗细胞毒性 T 淋巴细胞抗原4(CTL A-4)、抗程序性细胞死亡1(PD-1)和抗程序性细胞死亡1配体1(PD- L1)抗体。ICIs的使用也导致了一系列新的免疫相关不良反应，其中皮肤相关不良反应较为常见。本文综述了ICIs皮肤相关不良反应及其管理。

关键词: 免疫检测点抑制剂, 免疫相关不良反应, 皮肤

Abstract: The  immune-checkpoint inhibitors (ICIs) are the most important development on oncotherapy in the past decade, which includes anti-cytotoxic T lymphocyte antigen 4, anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1(PD-L1) antibodies. However, they bring a new spectrum of immune-related adverse events (irAEs), of which cutaneous adverse effects are most common. This article reviews the skin-related adverse reactions and management of ICIs.

Key words: immune-checkpoint inhibitors, immune-related adverse events, skin